What do systematic reviews say?

Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)

Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)

Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

Serious adverse events (at 48 weeks to 2 years) · Participants with Crohn's disease in remission